Is semaglutide patented in Singapore?
Semaglutide is protected by patents (and related patent families) covering key aspects of the drug, such as the molecule and its use. In Singapore, the enforceability and exact scope depend on which specific patent(s) were filed there and which claims are currently in force. Patent status also can differ by salt/formulation and by the particular medical use claimed.
How do you check whether a specific semaglutide patent is still valid in Singapore?
To determine current protection, you typically need to:
- Identify the exact Singapore patent publication numbers (and/or assignee/owner) tied to semaglutide in Singapore.
- Check whether each patent is in force (not expired or lapsed) and note relevant claim scope.
- If the question is about when the market can change, look for any granted extensions or rights that may affect exclusivity.
The most reliable approach is to search Singapore’s patent records using the patent holder name and semaglutide-related keywords, then verify the legal status.
When would a semaglutide patent expire in Singapore?
In general, pharmaceutical patents expire about 20 years from the earliest effective filing date, but the actual Singapore expiry date can shift based on:
- The earliest priority date in the patent family.
- The specific claim set filed and granted in Singapore.
- Any adjustments/extensions that may apply under local law for certain drug-related rights (this varies by jurisdiction and legal framework).
The exact expiry date requires the earliest priority and the specific Singapore patent number(s).
Can generics or biosimilars enter Singapore before semaglutide patent expiry?
Potentially, but only if they can lawfully launch without infringing in-force patent claims. Two common pathways are:
- Challenging patents (so-called “early” entries after invalidation/settlement).
- Launching products that avoid infringement by not covering the protected claims (for example, by focusing on different claims or using non-infringing design/use positioning).
If a patent still covers the relevant semaglutide use or composition in Singapore, entry is usually blocked until the protection ends or is successfully cleared.
What if you meant Ozempic/Wegovy (brand) versus “semaglutide” generally?
Semaglutide is sold under different brand names (and in different dosing regimens). Patent coverage can be broader than just “semaglutide as a chemical,” and may include specific medical uses, dosing schedules, or formulations. That means “semaglutide patent expiry” for one product or indication may not match another product’s protection timeline.
What information do you need from me to give an accurate answer?
If you share any of the following, I can narrow it down to the most relevant Singapore protection timeline:
- The brand name you mean (Ozempic, Wegovy, Rybelsus, or generic semaglutide)
- The patent holder/company name (if you have it)
- Any Singapore patent/publication number you’re looking at
- Whether you care about composition protection or a particular use/indication